发明名称 Methods and Compositions for Infusion of Transiently Engrafting, Selected Populations of Allogeneic Lymphocytes to Treat Cancer
摘要 The invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host.
申请公布号 US2015132290(A1) 申请公布日期 2015.05.14
申请号 US201314398724 申请日期 2013.03.15
申请人 The Johns Hopkins University 发明人 Fuchs Ephraim Joseph;Symons Heather Jills;Swinnen Lode
分类号 A61K35/17;A61K31/664;A61K45/06;C12N5/0783 主分类号 A61K35/17
代理机构 代理人
主权项 1. A method of making an allogenic lymphocyte composition comprising: providing a peripheral blood cell composition from a human donor allogenic to the recipient, the peripheral blood cell composition comprising CD4+ T-cells, CD8+ T-cells, and natural killer cells, wherein (i) the donor comprises at least one human leukocyte antigen (HLA) Class II allele mismatch relative to the recipient in the donor versus the recipient direction and the HLA Class II allele mismatch is at a gene selected from the group consisting of HLA-DRB1, HLA-DQB1, and HLA-DPB1, and (ii) the recipient does not have detectable antibodies reactive against human leukocyte antigens of the donor.
地址 Baltimore MD US